First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation


Цитировать

Полный текст

Аннотация

Adagrasib is an orally bioavailable, highly selective, small-molecule, irreversible covalent inhibitor of KRASG12C. It was approved by the US FDA on December 12, 2022, for patients with tumors harboring the KRASG12C mutation in locally advanced or metastatic non-small cell lung cancer (NSCLC). Herein, synthesis, dosage and administration, mechanism of action, pharmacokinetics, pharmacodynamics, and adverse events of adagrasib are described.

Об авторах

Surya De

Department of Chemistry, Conju-Probe

Автор, ответственный за переписку.
Email: info@benthamscience.net

Список литературы

  1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249. doi: 10.3322/caac.21660 PMID: 33538338
  2. Thein, K.Z.; Biter, A.B.; Hong, D.S. Therapeutics targeting mutant KRAS. Annu. Rev. Med., 2021, 72(1), 349-364. doi: 10.1146/annurev-med-080819-033145 PMID: 33138715
  3. Corral de la Fuente, E.; Olmedo Garcia, M.E.; Gomez Rueda, A.; Lage, Y.; Garrido, P. Targeting KRAS in non-small cell lung cancer. Front. Oncol., 2022, 11, 792635. doi: 10.3389/fonc.2021.792635 PMID: 35083149
  4. Tian, H; Yang, Z; He, J. Adagrasib: A landmark in the KRASG12C-mutated NSCLC. Med. Comm. (2020), 2022, 3(4), e190. doi: 10.1002/mco2.190
  5. Cox, A.D.; Fesik, S.W.; Kimmelman, A.C.; Luo, J.; Der, C.J. Drugging the undruggable RAS: Mission possible? Nat. Rev. Drug Discov., 2014, 13(11), 828-851. doi: 10.1038/nrd4389 PMID: 25323927
  6. Jänne, P.A.; Riely, G.J.; Gadgeel, S.M.; Heist, R.S.; Ou, S.H.I.; Pacheco, J.M.; Johnson, M.L.; Sabari, J.K.; Leventakos, K.; Yau, E.; Bazhenova, L.; Negrao, M.V.; Pennell, N.A.; Zhang, J.; Anderes, K.; Der-Torossian, H.; Kheoh, T.; Velastegui, K.; Yan, X.; Christensen, J.G.; Chao, R.C.; Spira, A.I. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N. Engl. J. Med., 2022, 387(2), 120-131. doi: 10.1056/NEJMoa2204619 PMID: 35658005
  7. Ou, S.H.I.; Jänne, P.A.; Leal, T.A.; Rybkin, I.I.; Sabari, J.K.; Barve, M.A.; Bazhenova, L.; Johnson, M.L.; Velastegui, K.L.; Cilliers, C.; Christensen, J.G.; Yan, X.; Chao, R.C.; Papadopoulos, K.P. First-in-human phase I/IB dose-finding study of Adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1). J. Clin. Oncol., 2022, 40(23), 2530-2538. doi: 10.1200/JCO.21.02752 PMID: 35167329
  8. Hallin, J.; Engstrom, L.D.; Hargis, L.; Calinisan, A.; Aranda, R.; Briere, D.M.; Sudhakar, N.; Bowcut, V.; Baer, B.R.; Ballard, J.A.; Burkard, M.R.; Fell, J.B.; Fischer, J.P.; Vigers, G.P.; Xue, Y.; Gatto, S.; Fernandez-Banet, J.; Pavlicek, A.; Velastagui, K.; Chao, R.C.; Barton, J.; Pierobon, M.; Baldelli, E.; Patricoin, E.F., III; Cassidy, D.P.; Marx, M.A.; Rybkin, I.I.; Johnson, M.L.; Ou, S.H.I.; Lito, P.; Papadopoulos, K.P.; Jänne, P.A.; Olson, P.; Christensen, J.G. The KRASG12C Inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov., 2020, 10(1), 54-71. doi: 10.1158/2159-8290.CD-19-1167 PMID: 31658955
  9. Sabari, J.K.; Velcheti, V.; Shimizu, K.; Strickland, M.R.; Heist, R.S.; Singh, M.; Nayyar, N.; Giobbie-Hurder, A.; Digumarthy, S.R.; Gainor, J.F.; Rajan, A.P.; Nieblas-Bedolla, E.; Burns, A.C.; Hallin, J.; Olson, P.; Christensen, J.G.; Kurz, S.C.; Brastianos, P.K.; Wakimoto, H. Activity of Adagrasib (MRTX849) in brain metastases: Preclinical models and clinical data from patients with KRASG12C-mutant non-small cell lung cancer. Clin. Cancer Res., 2022, 28(15), 3318-3328. doi: 10.1158/1078-0432.CCR-22-0383 PMID: 35404402
  10. Fell, J.B.; Fischer, J.P.; Baer, B.R.; Blake, J.F.; Bouhana, K.; Briere, D.M.; Brown, K.D.; Burgess, L.E.; Burns, A.C.; Burkard, M.R.; Chiang, H.; Chicarelli, M.J.; Cook, A.W.; Gaudino, J.J.; Hallin, J.; Hanson, L.; Hartley, D.P.; Hicken, E.J.; Hingorani, G.P.; Hinklin, R.J.; Mejia, M.J.; Olson, P.; Otten, J.N.; Rhodes, S.P.; Rodriguez, M.E.; Savechenkov, P.; Smith, D.J.; Sudhakar, N.; Sullivan, F.X.; Tang, T.P.; Vigers, G.P.; Wollenberg, L.; Christensen, J.G.; Marx, M.A. Identification of the clinical development candidate MRTX849, a covalent KRAS G12C inhibitor for the treatment of cancer. J. Med. Chem., 2020, 63(13), 6679-6693. doi: 10.1021/acs.jmedchem.9b02052 PMID: 32250617
  11. Dunnett-Kane, V.; Nicola, P.; Blackhall, F.; Lindsay, C. Mechanisms of resistance to KRASG12C inhibitors. Cancers, 2021, 13(1), 151. doi: 10.3390/cancers13010151 PMID: 33466360
  12. Christensen, J.G.; Olson, P.; Briere, T.; Wiel, C.; Bergo, M.O. Targeting Kras g12c ‐mutant cancer with a mutation‐specific inhibitor. J. Intern. Med., 2020, 288(2), 183-191. doi: 10.1111/joim.13057 PMID: 32176377
  13. Brazel, D.; Arter, Z.; Nagasaka, M. A long overdue targeted treatment for KRAS mutations in NSCLC: Spotlight on Adagrasib. Lung Cancer, 2022, 13, 75-80. doi: 10.2147/LCTT.S383662 PMID: 36387582
  14. Romero, D. Two new agents target KRASG12C. Nat. Rev. Clin. Oncol., 2020, 17(1), 6. doi: 10.1038/s41571-019-0304-3 PMID: 31772333
  15. Skoulidis, F.; Li, B.T.; Dy, G.K.; Price, T.J.; Falchook, G.S.; Wolf, J.; Italiano, A.; Schuler, M.; Borghaei, H.; Barlesi, F.; Kato, T.; Curioni-Fontecedro, A.; Sacher, A.; Spira, A.; Ramalingam, S.S.; Takahashi, T.; Besse, B.; Anderson, A.; Ang, A.; Tran, Q.; Mather, O.; Henary, H.; Ngarmchamnanrith, G.; Friberg, G.; Velcheti, V.; Govindan, R. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med., 2021, 384(25), 2371-2381. doi: 10.1056/NEJMoa2103695 PMID: 34096690
  16. Koga, T.; Suda, K.; Fujino, T.; Ohara, S.; Hamada, A.; Nishino, M.; Chiba, M.; Shimoji, M.; Takemoto, T.; Arita, T.; Gmachl, M.; Hofmann, M.H.; Soh, J.; Mitsudomi, T. KRAS secondary mutations that confer acquired resistance to KRASG12C inhibitors, sotorasib and adagrasib, and overcoming strategies: Insights from in vitro experiments. J. Thorac. Oncol., 2021, 16(8), 1321-1332. doi: 10.1016/j.jtho.2021.04.015 PMID: 33971321
  17. Awad, M.M.; Liu, S.; Rybkin, I.I.; Arbour, K.C.; Dilly, J.; Zhu, V.W.; Johnson, M.L.; Heist, R.S.; Patil, T.; Riely, G.J.; Jacobson, J.O.; Yang, X.; Persky, N.S.; Root, D.E.; Lowder, K.E.; Feng, H.; Zhang, S.S.; Haigis, K.M.; Hung, Y.P.; Sholl, L.M.; Wolpin, B.M.; Wiese, J.; Christiansen, J.; Lee, J.; Schrock, A.B.; Lim, L.P.; Garg, K.; Li, M.; Engstrom, L.D.; Waters, L.; Lawson, J.D.; Olson, P.; Lito, P.; Ou, S.H.I.; Christensen, J.G.; Jänne, P.A.; Aguirre, A.J. Acquired resistance to KRAS G12C inhibition in cancer. N. Engl. J. Med., 2021, 384(25), 2382-2393. doi: 10.1056/NEJMoa2105281 PMID: 34161704
  18. Kerr, D.L.; Haderk, F.; Bivona, T.G. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment. Curr. Opin. Chem. Biol., 2021, 62, 1-12. doi: 10.1016/j.cbpa.2020.11.007 PMID: 33418513
  19. Cascetta, P.; Marinello, A.; Lazzari, C.; Gregorc, V.; Planchard, D.; Bianco, R.; Normanno, N.; Morabito, A. KRAS in NSCLC: State of the art and future perspectives. Cancers, 2022, 14(21), 5430. doi: 10.3390/cancers14215430 PMID: 36358848
  20. Punekar, S.R.; Velcheti, V.; Neel, B.G.; Wong, K.K. The current state of the art and future trends in RAS-targeted cancer therapies. Nat. Rev. Clin. Oncol., 2022, 19(10), 637-655. doi: 10.1038/s41571-022-00671-9 PMID: 36028717
  21. Surya, K., Ed.; Fundamentals of Cancer Detection, Treatment, and Prevention; Wiley, 2022, pp. 259-284.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Bentham Science Publishers, 2024